View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 12, 2019

Puerto Rico approves investigation licence for first cannabis trial

The Commonwealth of Puerto Rico Medicinal Cannabis Regulatory Board has approved an investigation licence to conduct human clinical trials for evaluating medicinal cannabis.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

It is said to be the first cannabis trial in Puerto Rico since the Commonwealth government approved Medicinal Cannabis Act of 2017.

Veritas Pharma Puerto Rico, a division of Canada-based Veritas Pharma, will lead the clinical evaluation in partnership with the Institute for Medical Cannabis (IMC) and the Fundación de Investigación (FDI).

The trial will assess the partners’ lead cannabis candidate, CTL-X, in alleviating acute pain.

As part of the alliance, Veritas licensed the intellectual property related to its strains to IMC, which will provide samples to the FDI that will conduct direct research at its San Juan clinical research facilities.

FDI also has a 30-bed Phase I unit, an in-house bioanalytical laboratory, multi-specialty personnel and advanced medical technology.

Scheduled to be initiated this week, the medicinal cannabis trial is expected to be completed in three months.

Veritas Pharma director Nick Standish said: “The Veritas and Cannevert teams have worked very hard to get to this point, and this licence means we can take these next important steps forward that get us that much closer to having a marketable medical cannabis product, backed with real and credible science.”

The company aims to develop effective cannabis strains specifically for pain, nausea, epilepsy and post-traumatic stress disorder (PTSD). This will be made possible through investment in its wholly owned Puerto Rico subsidiary.

Veritas’ proposition is said to use a low-cost research and development model to accelerate shareholder value and speed-to-market.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena